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Abstract
Background: Targeted outreach, counselling, and treatment of sexually transmitted infections
(STIs) are among the most cost-effective interventions aimed at ameliorating the burden of HIV/
STIs. Since many new HIV infections occur in people under the age of 25, youth, and especially most
at risk adolescents (MARA), need to be able to access HIV/STI services. Starting in 2006, a
programme targeting MARA including outreach, confidential and voluntary counselling and testing,
and STI diagnosis and treatment was piloted in three cities in Tajikistan. This study uses data from
these pilot sites to estimate the costs of a national programme.
Methods: Cost data were collected from the three pilot sites. Then, the target population and the
number of patients receiving specific types of services are calculated for other areas. The unit costs
from the pilot sites are multiplied by usage rates to determine the total costs of a national
programme. Scenarios were developed to reflect data uncertainty. The government's ability to
finance the programme was estimated using Ministry of Health budget data. Further analyses were
done for one of the pilot cities where more detailed data were available.
Results: In total, costs were projected for eight programme sites, covering an estimated 8,020
MARA. Operational and variable cost for the programme are projected to be US$ 119,159 (range
US$ 104,953 to 151,524) per year. Including annual equivalent cost for capital and start-up items
raises this to US$ 137,082 (range: US$ 123,022 to 169,597) per year. The analyses of potential
sources of financing for the programme remain inconclusive, but it may take multiple sources of
financing to fund the programme.
Conclusion: While the cost-effectiveness of similar programmes have been previously assessed
using modelled data, more work needs to be done to assess the costs of new programmes in
relation to financial resources available. Full costing should consider cost-savings as well as
expenditures. If feasible, the impact of the programme should be monitored over time.
Background
Internationally, about 50% of HIV incidence cases are
among youth aged 15 to 24, which has led to an increased
concern with preventing the transmission of HIV among
this age group [1]. A recent systematic review points
towards the need to provide programmes that target
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youth, accommodate their needs, and provide assurances
of confidentiality and high quality treatment [1]. Specifi-
cally, for youth most at risk of HIV infection, increased
access to information and services, especially treatment of
sexually transmitted infections (STIs), were recom-
mended [1].
Targeted outreach, counselling, and treatment of STIs
have been shown to be among the most cost-effective
interventions in the prevention or care of sexually trans-
mitted infections including HIV/AIDS. For example, one
recent review found peer education and treatment of STIs
in sex workers to be the most cost-effective of all interven-
tions surveyed in South Asia, and the second most cost-
effective (after mass media) in the highest mortality
region of Africa [2]. Another review across low- and mid-
dle-income countries found peer education and outreach
to be the most cost-effective and STI diagnosis and treat-
ment the third most cost-effective of all HIV/AIDS inter-
ventions surveyed [3]. Both studies found these
interventions to be very cost-effective when compared
with public health interventions in general [4,5].
There remains, however, little information available on
the costs of both outreach to vulnerable populations and
the subsequent treatment of STIs [6], and almost no infor-
mation on the costs of programmes targeting youth. The
available information shows that unit costs at a particular
service site vary by country and by the volume of patients
[6-9]. While these cost data indicate that there is likely
economies of scale, or that there is a U-shaped long-run
average cost curve, in the delivery of STI treatment to com-
mercial sex workers (CSWs), these data alone do not pro-
vide information on the cost for the expansion of
programme services to areas where they were previously
unavailable [6,10]. Information on the number of people
to be served at new programme sites, together with data
on the variables that likely cause economies of scale, are
needed in order to plan for the costs of new or expanded
programmes.
This paper seeks to add to the literature assessing the costs,
and the costs of expanding, STI programmes. Specifically,
it provides cost-estimates for an outreach and STI treat-
ment programme targeting youths in Tajikistan. It uses
costs observed in three pilot sites to construct a cost pro-
jection for expanding the programme. Further, it assesses
possible sources of financing for the programme.
Methods
Setting
Starting in 2006, a programme encompassing outreach,
confidential and voluntary counselling and testing, and
STI diagnosis and treatment for most at risk adolescents
(MARA) was piloted at three sites in Tajikistan. This pro-
gramme was given technical and financial support by
UNICEF, and implemented by the Tajik Association of
Specialist in Dermatology and Venereal Diseases, Popula-
tion Services International, and the public health services
(all of which also provided some financial support), with
support from other Tajik NGOs and government agencies.
The pilot included regular outreach to MARA, with poten-
tial clients invited to newly established clinics (youth
friendly health services (YFHS)) for confidential counsel-
ling, diagnosis and treatment of STIs. Diagnosis and treat-
ment were offered free of charge, and condoms were
distributed free of charge both during outreach and at the
clinics. There are four main groups of most at-risk adoles-
cents (MARA) in Tajikistan: sex workers, intravenous drug
users (IDUs), men who have sex with men, and others
(mainly street children) [11].
The overall prevalence of HIV remains low in Tajikistan; it
is estimated that less than 1% of the population is HIV
positive [12]. However, high-risk populations show a
much higher HIV infection prevalence, with one 2004
report showing a 12% HIV prevalence among IDUs in
Dushanbe [13]. Government reports indicate the HIV
prevalence in Dushanbe and Khujand has reached as high
as 26% among IDUs [14]. Further, the prevalence of other
STIs is also high among sex workers with the prevalence of
syphilis estimated at 12% [11], while among youth tested
at pilot youth friendly health services, 39% were diag-
nosed with an STI [11].
General population knowledge about HIV/AIDS is low in
Tajikistan. The 2005 Multiple Indicator Cluster Survey
(MICS) showed only about 41% of the Tajik population
had heard of AIDS, and only about 23% of respondents
aged 15-19 years had heard of AIDS [15]. However, a
2006 survey of school children aged 13-15 years showed
that just under half of respondents reported being taught
about HIV in school, indicating that knowledge of HIV/
AIDS, while still low, is higher for children coming-of-age
over the next 5 years [16].
Among those that had heard of AIDS, about 32% of
respondents in the MICS survey could identify one
method of preventing HIV transmission, and only 11%
could name three prevention methods (16% and 5%,
respectively, among respondents aged 15-19 years) [15].
Among the 13-15 year old respondents of the school-
based survey, less than 4% correctly answered five ques-
tions about HIV transmission vectors [16]. Thus, while
knowledge of the existence of HIV is low, knowledge
about preventative measures is very low, and especially
low among adolescents. While data on sexual activity are
scarce, among the youths aged 13-15 years in the school
based survey, 13% reported having had sex in the last 12
months (of which more than half report using a condom),Cost Effectiveness and Resource Allocation 2009, 7:19 http://www.resource-allocation.com/content/7/1/19
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indicating that youths engaging in sex is not uncommon
in Tajikistan [16].
Just under 13% of the women surveyed in the MICS sur-
vey knew a place where they could get an HIV test; this
level was only 5% among 15-19 year old respondents
[15]. However, in the school-based survey, 37% of
respondents reported being taught a place where they
could get the HIV test [16].
In June 2007, Tajikistan started a pilot introduction of a
"Basic Benefit Package" (BBP) of health services in four
rayons. The BBP seeks to regulate health care recipients'
out-of-pocket payments, which account for an estimated
70% of health care financing, by introducing prospec-
tively determined formal co-payments for health services
from secondary-level facilities. The BBP decree defines a
'package' of services that will be exempt from co-payments
for attending patients based on patients' social status or
disease. This free benefit package includes "Anonymous
consultations about HIV/AIDS and STI" for the entire
population [17].
However, since most new HIV infections occur before the
age of 25, there remains a need for youth-targeted HIV
prevention outreach services (and not just the treatment
covered in the BBP), especially for MARA [1]. Youth-
friendly facilities are also needed to enable MARA to
access health services because youth under the legal age
are not covered under the BBP. Further, many MARA, due
to their situation, do not have official registration cards,
which are necessary to gain the benefits of the BBP pro-
gramme.
Target population
It is assumed that the programme needs to be expanded to
the major cities of Tajikistan. To determine the popula-
tion in need where the programme is to expand, the total
number of youth (age 15-25) was derived from city or
rayon-specific population figures. Then, the likely per-
centage of youth that are MARA was estimated by apply-
ing the percentage of youth that are MARA from the three
pilot areas to the new areas. The number of MARA in the
three pilot areas was determined using surveys conducted
after 6 months of programme operation, where the total
number of attendances at the YFHS facilities were multi-
plied upward based on the percentage of MARA inter-
viewed for the survey who had attended the YFHS [11].
The total number of MARA attending YFHS facilities and
receiving specific types of services are then calculated
based on facility records for the first year of operation in
the three pilot sites. Thus, the total number of facilities in
operation, the number in the target population, and the
number of patients receiving specific types of services are
calculated for all areas designated for programme scale-
up.
In some cases during the pilot, service utilization rates
were limited due to supply stock-outs. For example, out-
reach workers felt that more condoms could have been
distributed if supplies had been available; in two sites,
stock-out of STI diagnostic supplies was reported. In these
cases, in addition to the estimates based on the observed
data, the number of patients treated is also calculated
assuming these supplies would be available. These results
are presented in scenario analyses.
Costing
The study uses the government health system perspective.
The cost of the programme at the three pilot sites was
determined based on a review of programme and finan-
cial records and interviews with the three programme
managers. Both government and donor records were
reviewed. Costs were collected for the period of January
2007-June 2008 and converted to annual equivalent
quantities. All costs are presented as incremental to the
existing health system infrastructure.
Costs are classified into four categories for the purposes of
analysis:
1. Facility investment (start-up costs): Capital
improvements made at facilities so that they can offer
youth-friendly services to MARA. Costs in this category
include the purchase of furniture, medical equipment,
and laboratory equipment. Building and utility costs
were not considered since most facilities in Tajikistan
are under-utilized and needed space for this pro-
gramme should be available at future sites.
2. National level programme costs: Cost of training (of
medical staff), supervision, the design and printing of
informational brochures, and monitoring and evalua-
tion.
3. Facility level programme costs: The costs of the
operation of the programme at the facility level
include airing of media messages, establishing and
coordinating relations with other members of the
community, cost of outreach, cost of monitoring, and
the hire of a programme manager.
4. Variable costs: These include the costs incurred due
to patients seeking service at the YFHS facility and
cover counselling costs, consulting fees for the doctor,
HIV testing costs, STI diagnosis, and STI treatment
costs. The costs of services which require referral out-
side of the YFHS clinic, including management and
treatment of HIV/AIDS among those found positiveCost Effectiveness and Resource Allocation 2009, 7:19 http://www.resource-allocation.com/content/7/1/19
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for the virus, are not included in this analysis. Since
programme records include the number of people
contacted in outreach, but do not list the total number
of outreach contacts made, costs for outreach were
determined by finding the number of condoms and
brochures distributed and dividing by the number of
unique contacts.
Costs were calculated based on an ingredients approach,
multiplying the quantity of goods needed by the unit
price of each item, using Microsoft Excel [18]. Annualized
costs for goods with a lifespan of more than a year were
calculated using a 10% discount rate, and are reported
separately from routine costs. When necessary, prices were
converted to US dollars using official exchange rates
reported by the International Monetary Fund [19]. All
costs are reported for the year 2007.
Financing
In Tajikistan, the Family Medicine Programme has the
terms of reference to serve adolescents and was considered
one likely source of financing for programme scale-up. To
determine the adequacy of resources available in the Fam-
ily Medicine Programme, a series of different scenarios are
explored. All data were gained from the Tajikistan Minis-
try of Finance (MoF) and the Ministry of Health (MoH).
In the first scenario, MoF macroeconomic projections
through 2010 are used to determine the size of the overall
economy, and subsequently project the size of the govern-
ment budget. The percentage of the government budget
dedicated to health is also derived from MoF projections,
or, when these are unavailable, using the percentage from
the previous year (i.e., it is assumed that there will be no
change in the health budget as a percentage of the total
government budget).
To determine the amount of resources available for the
YFHS programme, the percentage of the health budget
devoted to the Family Medicine Programme is determined
based on historical budgets from the Ministry of Health
(MoH). This is projected into the future assuming the
Family Medicine Programme retains a constant percent-
age of the MoH's total budget. The amount of the Family
Medicine Programme intended for adolescents is deter-
mined based on the assumed utilization rates of different
age groups. However, these data are not available for each
of the areas intended for scale-up, so specific figures are
not available. Another potential source of financing
comes from the STI programme, and further scenarios are
developed based on data available for the STI budget at
one of the pilot sites.
Results
Target population
The target population used for the costing estimates is
shown in table 1. In total, eight sites were included, cov-
ering an estimated 8,020 MARA. The eight sites are located
in cities that have a combined total population (all ages)
of over 2 million, representing about 1/3rd of the popula-
Table 1: Estimated population in need and service utilization rates
Category Estimated/observed in 3 pilot 
sites
Projected for 8 national sites Ranges used in scenario analysis
Low High
Number of Youth 163,945 294,469
Number of MARA 4,068 8,020 4,906 10,507
Number of Facilities 3 8 8 8
Number of visits to YFHS per 
MARA per Year
0.602 0.602 0.602 0.800
Number of STI tests per YFHS visit 0.779 0.779 0.779 0.95
Number of HIV tests per YFHS 
visit
0.245 0.245 0.200 0.300
Number of STI infections treated 
per STI test
0.229 0.229 0.229 0.229
YFHS: Youth Friendly Health Services
MARA: Most at-risk adolescents
STI: Sexually Transmitted InfectionsCost Effectiveness and Resource Allocation 2009, 7:19 http://www.resource-allocation.com/content/7/1/19
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tion of Tajikistan, and encompass almost 294,000 youths.
Since the number of MARA is projected based on survey
data from the three pilot sites, ranges of the number of
MARA were also estimated based on the observed high
and low percentage of youth being MARA; these high and
low estimates are considered in scenario analysis (see
below). The estimated range of MARA covered is 4,906 to
10,507.
Service utilization rates are also shown in table 1, in which
all data collected from the pilot sites were converted to
annual rates. In the three pilot projects observed, there
were on average 0.6 visits per year per MARA, an average
of 0.77 STI tests per clinic visit, and 0.25 HIV tests per
clinic visit. Finally, the treatment rate for STIs was
observed at 0.23 per STI test performed. Programme man-
agers reported that the observed rates of STI testing were
lower than would have occurred in a fully supplied pro-
gramme, and that, given better quality of care or different
hours of operation, more MARA would be able to attend
the facility. Thus, increases in both rates were explored in
scenario analysis.
Costs
Tables 2 and 3 present the results of the costing analysis.
Facility investment (start-up costs)
In total, the capital investment in the pilot project aver-
aged US$ 16,789 per site (US$ 3,293 annualized). Pur-
chase of new medical equipment constituted over half of
the total capital investment.
National level and facility level programme costs
Most of the national level programme costs are consid-
ered operational costs with the exception of training,
which is considered a start-up cost. Supervision and the
development of informational materials together are esti-
mated to costs US$ 13,215 per year. The cost of running
the programme at each facility is estimated at US$ 7,764
per year, for a total of US$ 62,112 per year. About 42% of
the programme costs at the facility level are for running
the outreach programme.
Variable costs
The unit costs of diagnosing and treating sexually trans-
mitted infections (STIs) are detailed in table 2. Not shown
in table 2 is the estimated cost per outreach contact. This
is estimated to be US$ 1.96 for condoms and brochures
per unique contact per year.
It is assumed for purposes of costing that the rapid test for
syphilis would be procured and routinely used in the pro-
Table 2: Variable costs: Unit costs for HIV and STI testing and STI treatment
HIV Tests Number Unit Costs
(US$)
Cost per Episode
Lab test - Rapid Test 1 0.87 0.87
Lab test - Elisa 10% 1.88 0.19
Total for HIV Testing 1.05
STI Tests Percentage observed in 3 pilot sites Unit Costs
(US$)
Weighted Cost
Test for gonorrhoea 34% 3.20 1.07
Test for syphilis 28% 1.56 0.44
Test for herpes 0% 3.49 0.00
Test for Chlamydia 4% 3.20 0.11
Pregnancy Test 2% 0.10 0.00
Urine Test 2% 2.91 0.06
Test for trichomoniasis 31% 3.20 0.99
Average Unit Costs 2.68
STI Treatment Percentage observed in 3 pilot sites Unit Costs
(US$)
Weighted Cost
Treatment for gonorrhoea 48% 7.43 3.53
Treatment for syphilis 5% 2.83 0.13
Treatment for herpes 0% 1.16 0.00
Treatment for Chlamydia 1% 7.65 0.11
Treatment for trichomoniasis 46% 0.31 0.14
Average Unit Costs 3.91
STI: Sexually transmitted infectionsCost Effectiveness and Resource Allocation 2009, 7:19 http://www.resource-allocation.com/content/7/1/19
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Table 3: Estimated financial cost of YFHS programme year 2008-2010
Description Unit Price Pilot -- Operational 
Costs
National Programme -- 
Operational Costs
National Programme -- 
Including Annualized 
Costs
% of total costs
Capital Cost
Facility Start up 
(cost per facility)
16,789
Number of Additional 
Facilities
5
Total Costs for Capital 
Investment
3,293 12%
(10% - 13%)
Subtotal: Capital 
Costs
3,293 12%
(10% - 13%)
Programme Costs
For entire programme
Development of materials 145 145 145
Number of Operating 
Facilities
38
Supervision 1,488 4,465 11,907 11,907 9%
(7% - 10%)
Training (start-up) 2,862 - - 1,602 1%
(1% - 1%)
Booklets 145 436 1,163 1,163 1%
(1% - 1%)
Media 1,090 3,270 8,721 8,721 6%
(5% - 7%)
Personnel 2,093 6,279 16,744 16,744 12%
(10% - 14%)
Community Relations 1,265 3,794 10,116 10,116 7%
(6% - 8%)
Outreach 3,258 9,774 26,065 26,065 19%
(15% - 21%)
Monitoring and 
evaluation
58 174 465 465 0%
(0% - 0%)
Subtotal: Programme 
Costs
28,338 75,325 76,929 56%
(45% - 62%)
Variable Costs Unit Price Pilot -- Operational 
Costs
Operational Costs Annual Costs % of total costs
Outreach contacts 1.96 2064 4069
Facility visits 4.42 2449 4828
(2954 - 8406)
STI Tests 2.68 1882 3710
(2270 - 7985)
HIV Tests 1.05 600 1183
(591 - 2522)
STI Treatments 3.91 430 849
(519 - 1826)
Total cost for outreach 
contact
4,046 7,977 7,977 5%
(5% - 6%)
Total cost for facility 
visits
10,819 21,330
(13,049 -- 37,138)
21,330
(13,049 -- 37,138)
13%
(11% - 22%)
Total cost of STI tests 5,052 9,961
(6,094 -- 21,437)
9,961
(6,094 -- 21,437)
6%
(5% - 13%)Cost Effectiveness and Resource Allocation 2009, 7:19 http://www.resource-allocation.com/content/7/1/19
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gramme; unit costs reflect this assumption. The relative
weight given to each disease is based on the experience of
the three pilot sites. The average cost per person tested is
estimated at US$ 2.68, while the average cost per STI case
treated is estimated at US$ 3.91.
Total costs
Table 3 summarized the cost projections. Cost are pre-
sented for the 3 pilot sites, for the yearly operational costs
of running the expanded programme (excluding capital
and start-up costs), and including all costs, with capital
and start-up costs included as the annual equivalent costs.
Operational and variable cost when the programme is
fully operational are projected to be US$ 119,159, ranging
from US$ 104,953 to 151,524. Including annual equiva-
lent cost for capital and start-up items raises this to US$
137,082 (range: US$ 123,022 to 169,597).
Capital improvement at facilities represents 12% of the
costs. Programme costs and facility level programme costs
represent 56% of costs, and the costs for medical services,
diagnosis, and treatment represent 32% of the costs
(Table 3 presents the ranges for these percentages based
on the scenarios).
Financing
An analysis of the costs and the financing together is pre-
sented in table 4, table 5, and table 6. Table 4 shows the
cost per recipient, per target population, and per capita.
The annual cost (excluding capital costs) for the three
pilot areas is estimated at US$ 12.43 per targeted MARA
(and about US$ 0.04 per youth). This increases to US$
14.86 per MARA (range US$ 14.37 to 21.28) in the pro-
jected scale up; the difference is due to the smaller target
population per clinic, on average, in the non-pilot sites.
Including the equivalent annual costs for capital items
raises the cost per MARA to about US$ 17.09.
Total cost of HIV tests 632 1,246
(622 -- 2,655)
1,246
(622 -- 2,655)
1%
(1% - 2%)
Total cost of STI 
Treatments
1,683 3,318
(2,030 -- 7,140)
3,318
(2,030 -- 7,140)
2%
(2% - 4%)
Subtotal: Variable 
Costs
22,233 43,832 43,832 32%
Subtotal: Range for 
variable costs
(29,772 -- 76,347) (29,772 -- 76,347) (24% - 45%)
TOTAL COSTS for 
programme
50,571 119,103 137,082
RANGE: TOTAL COSTS 
for programme
(104,953 -- 151,528) (123,022 -- 169,597)
STI: Sexually Transmitted Infections
Table 3: Estimated financial cost of YFHS programme year 2008-2010 (Continued)
Table 4: Financial analysis of YFHS programme: Cost per person
Observed in 3 pilot sites For programme at full implementation Range for programme
Low High
Number in Target Population
MARA 4,068 8,020 4,906 10,507
Youth 163,945 294,469
Population (total) 1,303,594 2,024,457
Total Yearly Costs (does not include capital costs)
Estimate 50,571 119,159 104,953 151,528
Yearly Costs (does not include capital costs)
Per MARA 12.43 14.86 21.28 14.37
Per Youth 0.31 0.40 0.35 0.51
Per Capita 0.04 0.06 0.05 0.07
Yearly Costs (including annualized capital costs)
Per MARA 17.09 15.34 21.15
Per Youth 0.47 0.42 0.58
Per Capita 0.07 0.06 0.08
MARA: Most at-risk adolescentsCost Effectiveness and Resource Allocation 2009, 7:19 http://www.resource-allocation.com/content/7/1/19
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Table 5 compares the costs and the financing. The Family
Medicine budget from Ministry of Health records was
available for 2 of the 3 pilot sites (Dushanbe and Tursun-
zade), and the costs for these two pilot sites are compared
to the budget in the first two columns. The two areas had
a total Family Medicine budget of over US$ 3 million; it is
estimated that about US$ 350,000 of this is allocated for
youth. The cost of the pilot programme is estimated to be
about 9.9% of this 'youth budget'.
The right hand side of the table uses national figures to
assess the costs of the YFHS programme on a wider scale.
Here, it is estimated that about US$ 7.1 million of the
Family Medicine budget is targeted at youth. The YFHS
programme costs represent 1.7% of that budget. However,
the areas targeted for scale-up only cover about 1/3rd of
the population of Tajikistan, indicating that the YFHS pro-
gramme could represent 5-6% of the 'youth budget' in the
scale-up areas.
Finally, data were available in Tursunzade to do further
analyses of possible financing sources for the YFHS pro-
gramme. Table 6 provides details for two scenarios. In the
first scenario, the budget for primary health care is ana-
lyzed. Two standards for cost per capita are used: US$ 0.37
(which is the national standard) and US$ 2.32 (which is
the budget in Tursunzade). Based on the population and
the standard costs per capita, a total budget for youth is
estimated. The YFHS programme would represent 134%
of the youth budget based on the national standard, but
only 21% of the budget based on the Tursunzade stand-
ard. Similarly, Scenario 2 shows the YFHS programme
budget as 91% of Tursunzade's STI programme budget.
Table 5: Financial analysis of YFHS programme: Initial analysis
Budget in Dushanbe (2008) Budget in Tursunzade 
(2008)
National Health Budget Range
Low High
Current Budget for youth
Budget for Family Medicine 
Programme
2,627,903 589,814 18,814,620
Budget for youth 228,839 124,605 7,134,332
YFHS programme yearly costs 
(excluding capital) as percentage 
of youth budget
9.7% 15.8% 1.7% 1.7% 1.9%
YFHS yearly costs (excluding 
capital) as percentage of youth 
budget
1.9%
*Realization rate from 2007 applied to budget for 2008 for Dushanbe and Tursunzade; 95% realization rate assumed for National Health Budget
YFHS: Youth Friendly Health Services
MARA: Most at-risk adolescents
Table 6: Financial analysis of YFHS programme: Alternatives for Tursunzade
Scenario 1: Budget based on state standard per capita expenditure and 
number of youth visits
Formula/notes
a. Youth aged 13-19 39,657 39,657
b. State standard health budget per capita 0.37 2.32 $0.37 is state standard allocation; $2.32 is the annual budget for 
primary health care per capita in Tursunzade
c. Budget for youth according to standard 14,641 91,995 = a × b
Programme routine costs as percentage of youth 
budget
134% 21%
Scenario 2: Budget based on STI and dermatologic in-patient services Formula/notes
a. State standard budget for 1 bed-day 11.2
b. Total annual budget for STI/dermatologic in-
patient services (BBP)
21,717 From MoH records
Programme routine costs as percentage of STI 
budget
91%
YFHS: Youth Friendly Health Services
MARA: Most at-risk adolescentsCost Effectiveness and Resource Allocation 2009, 7:19 http://www.resource-allocation.com/content/7/1/19
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Discussion
The costing done for this report includes many assump-
tions. The most important is that the activities observed in
the pilot reflect what is needed for a national programme.
Based on data observed from the pilot projects, outreach
comprises about 42% of the yearly costs of running the
programme at the facility level. The exact nature of out-
reach activities needed, and that are effective, needs fuller
assessment. The relatively short term nature of the pilot
projects do not give adequate information to assess the
extent to which outreach worker turnover will affect the
quality of the programme and necessitate additional
training sessions in the future. Further, quality staff at
higher levels will be needed to engage in training and
supervision of the programme staff to ensure that high
quality implementation is maintained.
Capital costs are likely to be dependent on the existing sit-
uation in different sites for the YFHS. What is presented is
a best first estimate; more detailed planning and budget-
ing will be needed as the project is expanded. The price of
many of the goods was obtained from international agen-
cies that have tax exempt status. It is not clear if the Min-
istry of Health is able to procure some or all of these goods
tax-free or on such favourable terms as international agen-
cies.
The population at risk, reached, and treated is also highly
uncertain. The pilot sites represented the capital city and
two cities near Tajikistan's borders, which may not reflect
the situation in all areas of Tajikistan. This is dealt with by
using different scenarios to estimate the total costs of the
programme. More detailed decisions are needed on where
YFHS targeting MARA will be located. The scenarios show
a range of just under US$ 50,000 in annual costs (exclud-
ing capital costs) is possible. However, the extent of the
costs are, at least somewhat, in the control of the pro-
gramme. For example, ensuring adequate supplies will
increase the likelihood that patients who need a diagnos-
tic test will receive one. Ensuring adequate outreach and
clinic hours will also likely mean that more of the target
population accesses the clinic. Thus, poor logistics and
support will lower the cost of the programme (de facto
resulting in rationing and poor quality of care) while good
logistics and support will result in greater costs (and also
greater effectiveness).
The rates observed in the pilot project are likely to under-
estimate the need for visits and testing in a fully opera-
tional programme, and potential ranges were estimated to
explore the impact on the total costs of increasing the rates
of visits and testing. The assumptions of increased utiliza-
tion are contingent on a programme that will be able to
provide more outreach and better service and thus mar-
ginally increase clients' demand for services. It is assumed
that in a well funded programme there would be 0.8 clinic
visits per MARA. This is quite a bit higher than the
observed rate (0.6) and is intended to represent the maxi-
mum costs for the programme barring any major changes
in how it is implemented.
The observed rate of testing patients for STIs was 0.77 per
clinic visit; however, given the nature of the clientele, it is
likely that close to all visits would require a test. Thus, the
upper range is set at 0.95 tests per clinic visit. There were
no reported stock-outs of HIV tests in the pilot projects;
ranges are included only to explore the impact of patient
uptake of voluntary testing on the total costs.
The relative number of test performed are based on the
experiences of the three pilot project sites; however it is
unlikely that a different mix of tests would substantially
change the overall average cost for testing. The unit costs
for treatment across the diseases, on the other hand, show
more heterogeneity, with the treatment of gonorrhoea
and Chlamydia being more expensive than other diseases.
Thus, if the disease patterns experienced by the three pilot
sites do not reflect the disease patterns on a national level,
the cost of the programme would change.
The financing scenarios presented are incomplete. More
work is needed to clarify the amount of money that is
potentially available for financing YFHS, and potential
sources for this financing. It is estimated that in the target
areas, MARA represent 2.7% of the adolescent population.
In areas where budgets are available (Dushanbe and Tur-
sunzade), this programme represents about 10-15% of
funds estimated to be available for adolescents through
the Family Medicine programme. Clearly, MARA are in
greater need of medical services than many adolescents,
and their budget allocation and medical consumption
should consequently be higher than that of the average
adolescent. These extra costs need to be considered in the
light of the fact that the cost-effectiveness of STI interven-
tions is also highly favourable.
It should not be thought that the financing scenarios
included in this report are the only means of financing
this programme. For example, in the baseline case, the
projections estimate that about 3,700 laboratory tests will
need to be done. In the BPP pilot project, patients are
charged a user fee for laboratory tests; raising this user fee
to cover these 3,700 tests may be possible and represent
only a small increase in the per-test charge. Further, some
of the costs, such as capital investment or training, may be
funded by donors, as was the case for the pilot projects.
This study briefly assessed the Family Medicine and STI
departments as potential sources of funding for the YFHS
programme. It may also be the case that all (rather thanCost Effectiveness and Resource Allocation 2009, 7:19 http://www.resource-allocation.com/content/7/1/19
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just youth's 'fair share') of money in the Family Medicine
budget would be available for the YFHS programme.
In the longer term, gains in efficiency, reallocation of
funds away from inefficient programmes, and other
means of redirecting funds may also be possible. How-
ever, it is recommended that the Ministry of Health and
partners ensure that sustainable funding is available in the
medium to long term for facility level activities and the
procurement of pharmaceuticals and supplies. The best
conclusion to be drawn from the analysis remains, thus,
that more research is needed to understand the extent to
which governmental budget money can be a source of
funds for YFHS programmes.
Estimating the benefits of programmes is difficult, espe-
cially in the absence of direct knowledge about the effects
of the programme. The results presented here should then
be interpreted as conservative (i.e., high) estimates for the
cost of the programme because they do not include any
potential savings resulting from the decreased number of
STI cases as a result of the programme. Specific types of
preventative activities, which could influence the amount
of services born by the health system, include:
1. The benefits of increased use of condoms [20]. An
unknown percentage of MARA has STIs and do not get
treated by the YFHS programme but may be contacted
during outreach. In addition, condoms are distributed
to all MARA seeking treatment at the YFHS. While con-
dom usage rates (during the last sex act) among CSWs
overall appears to be over 50% [21], it is not known to
what extent this applies to MARA, or the effect the
YFHS programme has had on their condom usage
rates.
2. The benefits of other preventative activities (e.g.,
such as counselling, outreach messages, reduction in
the number of unwanted pregnancies) [20]. Some of
these benefits, such as reducing the spread of HIV due
to increased condom use, likely have a small effect cur-
rently given the low prevalence rate of HIV in
Tajikistan, but could have more substantial implica-
tions in the longer term.
3. Decrease in the transmission of STIs due to treat-
ment. Successful and timely treatment for STIs should
lessen, in many cases, the length of time for which
MARA are infectious, and thus reduce the number of
STI cases among the people having sex with MARA
[22-26].
Lacking data on transmission dynamics specific to either
Tajikistan or this programme, it is not possible to robustly
assess the extent of these benefits. Informal analysis
(available from the authors upon request) indicates it is
likely that, in net, the programme will cost the MoH
money, but the amount saved could be a considerable
proportion of the amount spent. That this informal anal-
ysis did not show that this programme will, in net, be cost
saving is due to the relatively large proportion of the YFHS
costs borne at the programme level compared with the
variable costs for diagnosing and treatment. This empha-
sizes the point made elsewhere that the full costs of a pro-
gramme, rather than just the medical costs, need to be
considered in estimating the costs as well as the cost-effec-
tiveness of a programme [27,28].
Conclusion
This study presents the costs and the potential sources of
financing for scaling-up a programme from the pilot stage
to an expanded level of coverage. It thus presents a practi-
cal financial analysis, following templates used at the glo-
bal level [29]. While there is global evidence to show that
the interventions analysed here are effective [1], the effec-
tiveness of the programme in the context of Tajikistan is
not known. There exists at the pilot level good data on uti-
lization and treatment, but further work could be done to
gain a better understanding of the impact of the pro-
gramme. This could be done either with sentinel surveil-
lance, or by tracking the level of STIs in MARA and other
STI programmes over time. Additionally, the cost of the
programme needs to be tracked over time to ensure that
budget allocations meet the needs of the programme.
The costs per case produced by this report are of similar
magnitude to international studies of the cost-effective-
ness of STI treatment [2,3]. This may seem somewhat sur-
prising since, for example, this study includes only the
incremental, rather than total, costs of the programme.
Thus, consultations fees for doctors are included, but their
base salary is excluded, and much of the capital infrastruc-
ture used in the programme is not included in the costs.
However, the concordance of findings does offer support,
from the cost side, to the evidence base that outreach to
and treatment of STIs in MARA is likely to be a very cost-
effective intervention and that there are few programmes
that will contribute more to disease aversion at a lower
cost per case prevented.
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